CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients

• Status: Active, not recruiting
• Trial end date: 2024-06-01

Summary

Although neoadjuvant radiotherapy greatly decreases local recurrence in locally advanced rectal cancer patients undergoing surgery, it inevitably results in short-term and long-term toxicities. More importantly, it has not been confirmed that neoadjuvant radiotherapy could improve overall survival. The purpose of this study is to compare the effects of chemotherapy alone using a combination regimen known as XELOX (capecitabine and oxaliplatin ) and selective use of the standard treatment to the standard treatment of chemotherapy and radiation.

• Phase: Phase 3

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborators: Affiliated Cancer Hospital of Shantou University Medical College; Cancer Hospital of Guangxi Medical University; First Affiliated Hospital of Chongqing Medical University; Fujian Cancer Hospital; Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial People's Hospital; Henan Cancer Hospital; Hubei Cancer Hospital; Jiangmen Central Hospital; Liaoning Tumor Hospital & Institute; Longyan City First Hospital; Meizhou People's Hospital; Shantou Central Hospital; Shengjing Hospital; The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Kunming Medical College; The First Affiliated Hospital with Nanjing Medical University; The Third Affiliated Hospital of Kunming Medical College.; West China Hospital; Zhejiang Cancer Hospital
• Treatments: Capecitabine; Oxaliplatin